By purchasing the MiniMed™ 670G system today, your patients will automatically be eligible for the Next Tech Pathway program, which helps them access our next technology when it’s released. The last day they can place an order and be enrolled is December 1, 2020.
Download a program flyer today to discuss with your patients.
The MiniMed™ 670G system offers SmartGuard™ technology, the only technology that mimics some of the functions of a healthy pancreas by providing two levels of automated insulin delivery.
SmartGuard™ Auto Mode:
Request information for your patients and a representative will follow up shortly.
The Next Tech Pathway program is available to any of your patients who purchase a MiniMed™ 670G system and meet one of the following requirements:
This program is not available to customers on a rental program such as those including but not limited to any federal, state, or other government-funded healthcare program like Medicare, Medicare Advantage, Medicaid, Medigap, the Department of Defense (“DOD”), or TRICARE.
See below for questions your patients may ask regarding the Next Tech Pathway program.
It can take several weeks to complete a purchase. However, Medtronic will work with your insurance plan and healthcare professional to process your order as quickly as possible.
All Next Tech Pathway upgrades must ship by 4/1/21. Upgrade requests following that date will not be honored. Medtronic will start accepting upgrade requests following the release of our next technology. Anyone that takes part in the program will be notified when and how requests can be submitted to Medtronic.
There is no upfront cost to upgrade through the program. You will be required to return your MiniMed™ 670G pump and transmitter within 90 days of your new product shipment. If you do not return your old devices within 90 days, you will be charged $3,200.
No, your warranty coverage will stay the same. For example, if the warranty of your MiniMed™ 670G pump ends on 9/29/23, your upgraded pump will still have warranty coverage through 9/29/23.
The Next Tech Pathway program is only available to those whose MiniMed™ 670G system shipped starting on 11/7/19. The final day to place an order and be enrolled in the program is 12/1/20. For current customers who purchased outside of that window, Medtronic are working on new upgrade programs. Please check their device upgrade page after our next technology release to see what upgrade options are available for you.
The Next Tech Pathway program is only valid for our next technology release. To upgrade to other future innovations, different upgrade programs will be available. Visit the Medtronic device upgrade page to learn more.
The Pathway program is for current Medtronic customers with an in-warranty pump. The Next Tech Pathway program is similar to the Medtronic standard Pathway but requires the purchase of a MiniMed™ 670G system within certain dates. Those who had a pump ship starting on 11/7/19 are eligible. The final day to place an order and be enrolled in the program is 12/1/20.
At this time, the program is exclusively available to those who buy the MiniMed™ 670G system. If you buy the MiniMed™ 630G system today and wish to upgrade during your warranty, we will have other upgrade options available for you. When new technology is released, please visit our device upgrade page to learn more about current offers.
There will be other upgrade options available during your warranty. Programs eligibility varies.
Refers to SmartGuard™ Auto Mode. Some user interaction required. Individual results may vary. The MiniMed™ 670G System can automatically increase or decrease insulin delivery based on continuous glucose monitoring (CGM) values; however, the user must still administer meal boluses. ADA recommendation for a glucose range is 80-180 mg/dL in non-pregnant adults with diabetes. Based on clinical study data in pivotal trial. Individual results may vary.
Based on sensor glucose.
dQ&A Patient Panel. [Q4 2016 Summary Report]. dQ&A 2017.
The Next Tech Pathway program (the “Program”) allows eligible, enrolled participants whose MiniMed™ 670G system order is shipped starting on 11/7/19 to be included. The last day to place an order is 12/1/20. This Program allows for an upgrade to our next MiniMed™ system at $0. Eligibility dates subject to change.
To be eligible for the Program, participants must purchase a MiniMed™ 670G system and meet one of the following requirements:
This program is not available to customers on a rental program such as those enrolled in federal, state, or other government-funded healthcare program like Medicare, Medicare Advantage, Medicaid, Medigap, the Department of Defense (“DoD”) or TRICARE.
To upgrade through the Program, all participants must agree and are subject to these terms and conditions:
The Medtronic MiniMed™ 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, seven years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 670G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on Continuous Glucose Monitor sensor glucose values and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian™ Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an Alternative Site (palm) or from a control solution test. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 670G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.
© 2020 Medtronic. All rights reserved. Medtronic, Medtronic logo and Further, Together are trademarks of Medtronic. Third party brands are trademarks of their respective owners. All other brands are trademarks of a Medtronic company.
Ascensia, the Ascensia Diabetes Care logo, and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.